Richard Ortiz, MD
Family Medicine · Kansas City, MONPI 1467410290
Payments from drug & device makers
Across 170 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$239
- GSK$232
- AbbVie$226
- Lilly USA, LLC$177
- AstraZeneca$138
- Boehringer Ingelheim$131
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,503100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $239 |
| GSK | 22 | $232 |
| AbbVie | 14 | $226 |
| Lilly USA, LLC | 13 | $177 |
| AstraZeneca | 2 | $138 |
| Boehringer Ingelheim | 9 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $113 |
| Amgen | 8 | $112 |
| Abbott | 7 | $111 |
| Sanofi-aventis U.S. LLC | 4 | $90 |
| Gilead | 6 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $75 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Astellas Pharma US Inc | 4 | $73 |
| Nevro Corp. | 2 | $56 |
| Novo Nordisk | 4 | $53 |
| Sunovion Pharmaceuticals Inc. | 4 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Amarin Pharma, Inc. | 3 | $41 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| Johnson & Johnson | 3 | $37 |
| Corcept Therapeutics | 2 | $31 |
| Genentech USA, Inc. | 2 | $29 |
| Daiichi Sankyo Inc. | 2 | $28 |
| Novartis | 2 | $27 |
| Ironwood Pharmaceuticals, Inc | 2 | $27 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Recor Medical Inc | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Vertex | 1 | $19 |
| Ardelyx, Inc. | 1 | $17 |
| Bayer | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,503 in reported general payments places this provider in the 75th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $104,282 |
| EliquisApixaban | 42 | $53,447 |
| MounjaroTirzepatide | 28 | $50,884 |
| TrulicityDulaglutide | 37 | $45,368 |
| JardianceEmpagliflozin | 19 | $31,042 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $22,741 |
| FarxigaDapagliflozin Propanediol | 14 | $22,101 |
| JanuviaSitagliptin Phosphate | 13 | $17,418 |
| XareltoRivaroxaban | 13 | $15,311 |
| TradjentaLinagliptin | 16 | $12,007 |
| OxycontinOxycodone Hcl | 14 | $10,997 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $10,294 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,619 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $7,780 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $7,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $53 | $104,28285 claims |
| Lilly USA, LLCMounjaro, Trulicity | $177 | $96,25265 claims |
| PfizerEliquis | $239 | $53,44742 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $131 | $50,06847 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arexvy | $232 | $35,94555 claims |
| AstraZenecaFarxiga, Symbicort | $138 | $26,19627 claims |
| MerckJanuvia | $19 | $17,41813 claims |
| Johnson & JohnsonXarelto | $37 | $15,31113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Kansas City
- Scott KuennenKansas City$2.2M
- Blair ThedingerKansas City$1.3M
- Heather JordanKansas City$70K
- Jon MattsonKansas City$53K
- Meredith LevineKansas City$26K
- Cindy ChangKansas City$22K
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.